Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1.-51. (Cancelled)

52.-75. (Not entered)

76.-104. (Cancelled)

105. (Not entered)

106. (Currently Amended) An isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells,

the composition being obtainable by:

(a) culturing murine or human embryonic stem cells that are not human genetically modified embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium;

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium; and

(d) culturing the cells from (c) in a third growth factor-containing serum-free medium, to obtain the cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells,

~~wherein the embryonic stem cells are murine or human embryonic stem cells and are not human genetically modified embryonic stem cells~~ thereby producing the isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells.

107. (Previously Presented) The cell composition according to claim 106, wherein the embryonic stem cells in step (a) are in the form of cell aggregates.

108. (Previously Presented) The cell composition according to claim 106, wherein the cells of steps (c) and (d) grow as a monolayer.

109. (Previously Presented) The cell composition according to claim 106, comprising cells with neuronal, astroglial or oligodendroglial properties.

110. (Previously Presented) The cell composition according to claim 106, wherein the embryonic stem cells are obtained after nuclear transfer into oocytes.

111. (Previously Presented) The cell composition according to claim 106, wherein the embryonic stem cells are obtained from embryonic germ cells.

112. (Previously Presented) The cell composition of claim 106, wherein the embryonic stem cells in (a) are cultured in serum-free medium.

113. (Previously Presented) The cell composition of claim 107, wherein the cell aggregates are embryoid bodies.

114. (Previously Presented) A cell library comprising cells according to claim 106, which are autologous and nonautologous cells.

115. (Canceled)

116. (Previously Presented) The cell composition according to claim 106, wherein the second growth factor-containing serum-free medium comprises bFGF and EGF.

117. (Previously Presented) The cell composition according to claim 106, wherein the third growth factor-containing serum-free medium comprises bFGF and PDGF.

118. (Currently Amended) An isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition comprising neural spheres, wherein the neural spheres consist

essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells,

the composition being obtainable by:

(a) culturing murine or human embryonic stem cells that are not human genetically modified embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium; and

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium to produce neural spheres consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells,

~~wherein the embryonic stem cells are murine or human embryonic stem cells and are not human genetically modified embryonic stem cells~~ thereby producing the isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition comprising neural spheres, wherein the neural spheres consist essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells.

119. (Previously Presented) The cell composition according to claim 118, wherein the embryonic stem cells in (a) are in the form of cell aggregates.

120. (Previously Presented) The cell composition of claim 119, wherein the cell aggregates are embryoid bodies.

121. (Previously Presented) The cell composition of claim 118, wherein the embryonic stem cells in (a) are cultured in serum-free medium.

122. (Previously Presented) The cell composition according to claim 118, wherein the embryonic stem cells are obtained after nuclear transfer into oocytes.

123. (Previously Presented) The cell composition according to claim 118, wherein the embryonic stem cells are obtained from embryonic germ cells.

124. (Previously Presented) A cell library comprising cells according to claim 118, which are autologous and nonautologous cells.

125. (Canceled)

126. (Previously Presented) The cell composition according to claim 118, wherein the second growth factor-containing serum-free medium comprises bFGF and EGF.

127. (Currently Amended) An isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition consisting essentially of embryonic stem cell-derived glial precursor cells, and glial cells derived from the embryonic stem cell-derived glial precursor cells,

the composition being obtainable by:

(a) culturing murine or human embryonic stem cells that are not human genetically modified embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium;

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium to produce neural spheres; and

(d) culturing the neural spheres from (c) in a third growth factor-containing serum-free medium to produce a monolayer of glial precursor cells, and glial cells derived from the embryonic stem cell-derived glial precursor cells,

~~wherein the embryonic stem cells are murine or human embryonic stem cells and are not human genetically modified embryonic stem cells~~ thereby producing the isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition consisting essentially of embryonic stem cell-derived glial precursor cells, and glial cells derived from the embryonic stem cell-derived glial precursor cells.

128. (Currently Amended) The cell composition according to claim ~~126~~ 127, wherein the embryonic stem cells in step (a) are in the form of cell aggregates.

129. (Previously Presented) The cell composition of claim 128, wherein the cell aggregates are embryoid bodies.

130. (Currently Amended) The cell composition of claim ~~126~~ 127, wherein the embryonic stem cells in (a) are cultured in serum-free medium.

131. (Currently Amended) The cell composition according to claim ~~126~~ 127, wherein the embryonic stem cells are obtained after nuclear transfer into oocytes.

132. (Currently Amended) The cell composition according to claim ~~126~~ 127, wherein the embryonic stem cells are obtained from embryonic germ cells.

133. (Currently Amended) A cell library comprising cells according to claim ~~126~~ 127, which are autologous and nonautologous cells.

134. (Canceled)

135. (Currently Amended) The cell composition according to claim ~~126~~ 127, wherein the second growth factor-containing serum-free medium comprises bFGF and EGF.

136. (Currently Amended) The cell composition according to claim ~~126~~ 127, wherein the third growth factor-containing serum-free medium comprises bFGF, EGF, or a combination thereof.

137. (New) A pharmaceutical composition comprising the an isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells,

the composition being obtainable by:

(a) culturing murine or human embryonic stem cells that are not human genetically modified embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium;

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium; and

(d) culturing the cells from (c) in a third growth factor-containing serum-free medium, to obtain the cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells,

thereby producing the isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells.

138. (New) A pharmaceutical composition comprising an isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition comprising neural spheres, wherein the neural spheres consist essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells,

the composition being obtainable by:

(a) culturing murine or human embryonic stem cells that are not human genetically modified embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium; and

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium to produce neural spheres consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells,

thereby producing the isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition comprising neural spheres, wherein the neural spheres consist essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells.

139. (New) A pharmaceutical composition comprising an isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition consisting essentially of embryonic stem cell-derived glial precursor cells, and glial cells derived from the embryonic stem cell-derived glial precursor cells,

the composition being obtainable by:

(a) culturing murine or human embryonic stem cells that are not human genetically modified embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium;

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium to produce neural spheres; and

(d) culturing the neural spheres from (c) in a third growth factor-containing serum-free medium to produce a monolayer of glial precursor cells, and glial cells derived from the embryonic stem cell-derived glial precursor cells,

thereby producing the isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition consisting essentially of embryonic stem cell-derived glial precursor cells, and glial cells derived from the embryonic stem cell-derived glial precursor cells.